Acurx Pharmaceuticals Stock Discussion

$Acurx Pharmaceuticals (ACXP.US)$
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...

$Acurx Pharmaceuticals (ACXP.US)$ Reuters· 3 mins ago
Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues

$Acurx Pharmaceuticals (ACXP.US)$
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...

$Acurx Pharmaceuticals (ACXP.US)$ Along with the FDA answer coming on phase 3!  (((((.  ·Throughout the rest of this year, they will continue to roll out our Phase 2 results in either oral presentations or scientific posters (in some cases both), which will include results from new analyses as data become available, at various prominent scientific conferences including:
oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...

$Acurx Pharmaceuticals (ACXP.US)$ Reuters· 7 mins ago
Uspto Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat Cdi While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

$Acurx Pharmaceuticals (ACXP.US)$
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the USPTO for ibezapolstat, its treatment for C. difficile Infection (CDI). The patent, issued on July 16, 2024, covers ibezapolstat's ability to treat CDI while reducing infection recurrence and improving gut microbiome health. This p...

$Acurx Pharmaceuticals (ACXP.US)$
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Acurx Pharmaceuticals (NASDAQ: ACXP) presented results from the ibezapolstat Phase 2 clinical trial for C. difficile Infection (CDI) at the 17th Biennial Congress of the Anaerobe Society of the Americas. The study showed favorable gut microbiome changes, including increased Actinobacteria in treated patients. Results were consistent wit...

$Acurx Pharmaceuticals (ACXP.US)$ Reuters· just
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program

$Acurx Pharmaceuticals (ACXP.US)$
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.